Invest now
Anthem BioSciences share price
Balanced risk
You have to be logged in to add this to Watchlist.- ₹930.50(4.37%)September 1, 2026 12:35:06 PM IST
- NSE
- BSE
- Vol : 825.37 K (NSE + BSE)Last 20 day avg : 855.94 K
Anthem BioSciences is trading 4.37% upper at Rs 930.50 as compared to its last closing price. Anthem BioSciences has been trading in the price range of 938.70 & 896.00. Anthem BioSciences has given 38.16% in this year & 3.29% in the last 5 days. Anthem BioSciences has TTM P/E ratio 75.18 as compared to the sector P/E of 45.64.There are 3 analysts who have initiated coverage on Anthem BioSciences. There are 0.00 analysts who have given it a strong buy rating & 2 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 119.94 Crores in its last quarter.Listed peers of Anthem BioSciences include Sun Pharmaceutical Industries (-1.47%), Divi's Laboratories (-0.90%), Torrent Pharmaceuticals (-0.38%).The Mutual Fund holding in Anthem BioSciences was at 11.15% in 30 Jun 2026. The MF holding has increased from the last quarter. The FII holding in Anthem BioSciences was at 2.57% in 30 Jun 2026. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Loading...
Key Metrics
Updated on 01 Sep 2026, 01:19 PM IST
- Debt To EquityLower than industry0.02The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.22Annual dividends as a percentage of the stock price.
- PEG RatioIndicates overvaluation5.90The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
- P/E-Price-to-earnings ratio based on trailing 12-month earnings
- P/B-The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- Beta-Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Anthem BioSciences News
Anthem BioSciences Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 1,927.15 | -1.47 | 4,62,376.94 | 38.40 | 5.55 | 0.83 | 0.47 |
| Divi's Laboratories | 9,162.00 | -0.90 | 2,43,222.31 | 73.32 | 11.48 | 0.41 | 0.03 |
| Torrent Pharmaceuticals | 4,959.00 | -0.38 | 1,88,617.68 | 72.73 | 19.22 | 0.80 | 141.16 |
| Cipla | 1,410.00 | -0.42 | 1,13,907.30 | 27.57 | 3.33 | 0.92 | 1.11 |
| Zydus Lifesciences | 1,170.50 | 0.72 | 1,16,757.82 | 21.19 | 4.24 | 0.09 | 14.22 |
Anthem BioSciences Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-07-21 | Quarterly Results |
| 2026-05-19 | Audited Results & Final Dividend |
| 2026-02-05 | Quarterly Results |
| 2025-11-08 | Quarterly Results |
| 2025-08-13 | Quarterly Results |
About the company Anthem BioSciences
- IndustryBiotechnology & Drugs
- ISININE0CZ201020
- BSE Code544449
- NSE CodeANTHEM
Anthem Biosciences Limited is an India-based contract research, development and manufacturing organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. The Company’s segments include CRDMO and Speciality Ingredients. The Company helps new and established biotech’s and big pharma, develop, optimize and test proteins, monoclonal antibodies, peptides, large molecules, small molecules, toxins and others. In addition to product research and development, it helps test drugs for safety, efficacy (in vitro and in vivo), pre-clinical animal studies in a GLP facility, clone development, antibody drug conjugates, research and development and manufacture of highly potent compounds, flow chemistry-based production and large-scale commercial product manufacture. Its CRDMO Services include Large Molecules, Small Molecules, HPAPI, Peptides, Lipids, ADCs and Oligonucleotides.
Anthem BioSciences Share Price FAQs
Anthem BioSciences is trading at 930.50 as on Tue Sep 01 2026 07:05:06. This is 4.37% upper as compared to its previous closing price of 891.50.
The market capitalization of Anthem BioSciences is 52425.11 Cr as on Tue Sep 01 2026 07:05:06.
The average broker rating on Anthem BioSciences is Buy. The breakup of analyst rating is given below -
- 0.00 analysts have given a strong buy rating
- 2 analysts have given a buy rating
- 1 analysts have given a hold rating
- 0.00 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Anthem BioSciences is 942.00 whereas the 52 wk low is 579.45
Anthem BioSciences can be analyzed on the following key metrics -
- TTM P/E: 75.18
- Sector P/E: 45.64
- Dividend Yield: 0.22%
- D/E ratio: -
Anthem BioSciences reported a net profit of 591.79 Cr in 2026.
The Mutual Fund Shareholding was 11.15% at the end of 30 Jun 2026.
Quick Links
EQUITY QUICK LINKS
Anthem BioSciences QUICK LINKS
FROM MARKETS
RELATED LINKS
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.